VIA
GENB

Virtus Investment Advisers’s Generate Biomedicines GENB Stock Holding History

Virtus Investment Advisers’s Portfolio GENB Stock Details GENB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$446K Buy
+26,430
New +$360K 0.1% 225

Other funds holding GENB

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Virtus Investment Advisers's GENB Position: Q2 2026 in Review

Virtus Investment Advisers opened a new position in Generate Biomedicines (GENB) in Q2 2026: 26,430 shares worth $446K. The stake represents 0.1% of the portfolio and ranks #225 among its holdings.

86 funds tracked by Wall St. Rank hold GENB as of Q2 2026.

  • Virtus Investment Advisers held 26,430 shares of Generate Biomedicines worth $446K as of Q2 2026.
  • Generate Biomedicines was a new Virtus Investment Advisers position in Q2 2026.
  • Generate Biomedicines made up 0.1% of Virtus Investment Advisers's portfolio in Q2 2026, its #225 holding.
  • 86 funds tracked by Wall St. Rank held Generate Biomedicines as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.